SLAS TECHNOLOGY,
Journal Year:
2023,
Volume and Issue:
28(3), P. 152 - 164
Published: April 3, 2023
Cancer
treatment
development
is
a
complex
process,
with
tumor
heterogeneity
and
inter-patient
variations
limiting
the
success
of
therapeutic
intervention.
Traditional
two-dimensional
cell
culture
has
been
used
to
study
cancer
metabolism,
but
it
fails
capture
physiologically
relevant
cell-cell
cell-environment
interactions
required
mimic
tumor-specific
architecture.
Over
past
three
decades,
research
efforts
in
field
3D
model
fabrication
using
tissue
engineering
have
addressed
this
unmet
need.
The
self-organized
scaffold-based
shown
potential
microenvironment
eventually
bridge
gap
between
2D
animal
models.
Recently,
three-dimensional
(3D)
bioprinting
emerged
as
an
exciting
novel
biofabrication
strategy
aimed
at
developing
compartmentalized
hierarchical
organization
precise
positioning
biomolecules,
including
living
cells.
In
review,
we
discuss
advancements
techniques
for
models,
well
their
benefits
limitations.
We
also
highlight
future
directions
associated
technological
advances,
detailed
applicative
research,
patient
compliance,
regulatory
challenges
achieve
successful
bed-to-bench
transition.
Theranostics,
Journal Year:
2024,
Volume and Issue:
14(3), P. 1101 - 1125
Published: Jan. 1, 2024
Cancer
remains
a
severe
public
health
burden
worldwide.One
of
the
challenges
hampering
effective
cancer
therapy
is
that
existing
models
hardly
recapitulate
tumor
microenvironment
human
patients.Over
past
decade,
organoids
have
emerged
as
an
in
vitro
3D
model
to
mimic
pathophysiological
characteristics
parental
tumors.Various
techniques
been
developed
construct
organoids,
such
matrix-based
methods,
hanging
drop,
spinner
or
rotating
flask,
nonadhesive
surface,
organ-on-a-chip,
bioprinting,
and
genetic
engineering.This
review
elaborated
on
cell
components
fabrication
methods
for
establishing
organoid
models.Furthermore,
we
discussed
application
modeling,
basic
research,
anticancer
therapy.Finally,
current
limitations
future
directions
employing
more
extensive
applications.
Cellular Oncology,
Journal Year:
2023,
Volume and Issue:
46(3), P. 503 - 519
Published: Jan. 25, 2023
Lung
cancer
is
the
most
common
and
leading
cause
of
cancer-related
death
worldwide.
However,
mechanisms
its
progression
remained
unclear
new
treatments
against
this
disease
are
rapidly
emerging.
As
a
novel
preclinical
model,
patient-derived
organoid
(PDO)
can
also
be
established
from
patient's
tumor
tissue
cultured
in
laboratory,
which
preserves
key
biological
characteristics
original
tumor.
Compared
to
xenograft
(PDX)
model
lung
cancer,
culture
success
rate
improved,
time
cost
establishment
largely
reduced.
PDO
expected
provide
more
individual
predict
efficacy
anti-cancer
treatment
vitro.
This
paper
summarizes
current
application
translational
research
cancer.
Coordination Chemistry Reviews,
Journal Year:
2024,
Volume and Issue:
508, P. 215754 - 215754
Published: March 12, 2024
The
science
of
nanotechnology
has
been
proposed
as
a
factor
main
change
in
the
field
cancer
diagnosis
and
treatment.
challenges
common
clinical
treatment
breast
can
be
dominate
by
proof
targeting
cells
nanoscale
drug
delivery
system.
Due
to
specific
properties
nanoparticles
such
biocompatibility,
minimum
toxicity,
excellent
stability,
multifunctional
encapsulations
therapeutic
agents,
increased
permeability
retention
effect,
selective
targeting,
they
apply
for
therapy.
Multidrug
resistance
many
chemotherapy
drugs
is
one
conventional
that
overcome
nanoparticles.
However,
vivo
vitro
studies
limited
this
field,
number
approved
nano
formulation
not
significantly
over
years.
Successful
translation
nanomedicines
arduous
requiring
considerable
preclinical
tests.
Two-dimensional
(2D)
monolayer
cell
cultures
animal
models,
which
are
routinely
used
research
discovery/screening
seem
inadequate.
To
address
challenge,
biomimetic
three-dimensional
(3D)
tumor
models
like
spheroids,
organoids,
scaffolds/hydrogels,
bioprinted,
microfluidic
chips
have
established
using
engineering
approach.
Taking
physiopathology
microenvironment
into
account,
potential
enhance
disease
modeling
drug/nanomedicine
screening.
development
3D
comprised
patient's
own
cancer,
stromal,
immune
exploited
promising
platform
provide
personalized
Biofabrication,
Journal Year:
2024,
Volume and Issue:
16(3), P. 032006 - 032006
Published: May 2, 2024
Abstract
Organoids
have
emerged
as
crucial
platforms
in
tissue
engineering
and
regenerative
medicine
but
confront
challenges
faithfully
mimicking
native
structures
functions.
Bioprinting
technologies
offer
a
significant
advancement,
especially
when
combined
with
organoid
bioinks-engineered
formulations
designed
to
encapsulate
both
the
architectural
functional
elements
of
specific
tissues.
This
review
provides
rigorous,
focused
examination
evolution
impact
bioprinting.
It
emphasizes
role
bioinks
that
integrate
key
cellular
components
microenvironmental
cues
more
accurately
replicate
complexity.
Furthermore,
this
anticipates
transformative
landscape
invigorated
by
integration
artificial
intelligence
bioprinting
techniques.
Such
fusion
promises
refine
bioink
optimize
parameters,
thus
catalyzing
unprecedented
advancements
medicine.
In
summary,
accentuates
pivotal
potential
advancing
therapies,
deepening
our
understanding
organ
development,
clarifying
disease
mechanisms.
Cancers,
Journal Year:
2025,
Volume and Issue:
17(1), P. 108 - 108
Published: Jan. 1, 2025
Background:
Tumor
organoid
and
tumor-on-chip
(ToC)
platforms
replicate
aspects
of
the
anatomical
physiological
states
tumors.
They,
therefore,
serve
as
models
for
investigating
tumor
microenvironments,
metastasis,
immune
interactions,
especially
precision
drug
testing.
To
map
changing
research
diversity
focus
in
this
field,
we
performed
a
quality-controlled
text
analysis
categorized
academic
publications
clinical
studies.
Methods:
Previously,
collected
metadata
on
organoids
or
organ-on-chip
from
PubMed,
Web
Science,
Scopus,
EMBASE,
bioRxiv,
published
between
January
2011
June
2023.
Here,
selected
documents
corpus
that
were
computationally
determined
relevant
to
analyzed
them
using
an
in-house
algorithm.
Additionally,
ClinicalTrials.gov
studies
related
ToC
March
Results
Discussion:
From
3551
139
trials,
identified
55
24
classes
modeled
models,
respectively.
The
was
particularly
active
neural
hepatic/pancreatic
organoids,
well
gastrointestinal,
neural,
reproductive
models.
Comparative
with
cancer
statistics
showed
lung,
lymphatic,
cervical
tumors
under-represented
research.
Our
findings
also
illustrate
varied
topics,
including
physiology,
therapeutic
approaches,
cell
involvement,
analytical
techniques.
Mapping
geographically
highlighted
colorectal
Netherlands,
though
overall
specific
countries
did
not
reflect
regional
prevalence.
These
insights
only
current
landscape
but
indicate
potential
new
directions
model
Biotechnology and Bioengineering,
Journal Year:
2022,
Volume and Issue:
119(10), P. 2669 - 2688
Published: June 29, 2022
In
the
current
pandemic,
scenario
world
is
facing
a
huge
shortage
of
effective
drugs
and
other
prophylactic
medicine
to
treat
patients
which
created
havoc
in
several
countries
with
poor
resources.
With
limited
demand
supply
drugs,
researchers
rushed
repurpose
existing
approved
for
treatment
COVID-19.
The
process
drug
screening
testing
very
costly
requires
steps
validation
efficacy
evaluation
ranging
from
in-vitro
in-vivo
setups.
After
these
steps,
clinical
trial
mandatory
side
effects
humans.
These
processes
enhance
overall
cost
sometimes
lead
molecule
show
adverse
humans
ends
up
final
stages.
Recently
advent
three-dimensional
(3D)
organoid
culture
mimics
human
tissue
exactly
can
be
done
faster
cost-effective
manner.
Further
3D
organoids
prepared
stems
cells
taken
individuals
beneficial
personalized
therapy
could
save
millions
lives.
This
review
discussed
approaches
techniques
synthesis
3D-printed
screening.
key
findings
usage
COVID-19
have
been
discussed.
end,
challenges
wide
applicability
prospects
future
orientation
included.
